Holen Sie sich die Stockscreener-App
192.03
0.03%
-0.05
Handel nachbörslich:
192.03
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$192.08
Offen:
$190.78
24-Stunden-Volumen:
795.15K
Relative Volume:
0.42
Marktkapitalisierung:
$28.18B
Einnahmen:
$9.69B
Nettoeinkommen (Verlust:
$1.61B
KGV:
17.51
EPS:
10.9652
Netto-Cashflow:
$2.26B
1W Leistung:
-2.28%
1M Leistung:
+16.11%
6M Leistung:
+38.16%
1J Leistung:
+40.09%
1-Tages-Spanne:
$189.95
$192.59
1-Wochen-Bereich:
$189.95
$200.29
52-Wochen-Spanne:
$110.03
$202.41
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, AZN, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
192.03 | 28.19B | 9.69B | 1.61B | 2.26B | 10.97 |
|
LLY
Lilly Eli Co
|
1,009.52 | 965.26B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
242.49 | 595.03B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
224.81 | 396.51B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
204.20 | 323.42B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
162.67 | 312.78B | 54.72B | 14.02B | 15.32B | 7.1855 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-09 | Bestätigt | H.C. Wainwright | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-10 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2025-11-06 | Hochstufung | Stifel | Hold → Buy |
| 2025-09-25 | Eingeleitet | Jefferies | Buy |
| 2025-07-21 | Fortgesetzt | Truist | Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
How (BIIB) Movements Inform Risk Allocation Models - Stock Traders Daily
Biogen Receives Honorable Mention From Fast Company's World Changing Ideas Awards - CSRwire
Biogen-Funded Collaboration with Americares and Harvard Chan C-CHANGE Recognized by the Clinton Global Initiative - CSRwire
Biogen Issues First Progress Report of its Signature Healthy Climate, Healthy Lives™ Initiative - CSRwire
Biogen Included in 2022 Bloomberg Gender-Equality Index - CSRwire
Skandinaviska Enskilda Banken AB publ Has $4.07 Million Position in Biogen Inc. $BIIB - MarketBeat
Barclays Upgrades Biogen (NASDAQ:BIIB) to Hold - MarketBeat
Barclays Initiates Coverage of Biogen (BIIB) with Equal-Weight Recommendation - Nasdaq
Beyond The Numbers: 21 Analysts Discuss Biogen Stock - Benzinga
Biogen’s BIIB091 MS Trial Reaches Completion, Setting Up a Key Pipeline Catalyst - TipRanks
Biogen (BIIB) Receives New Analyst Coverage with Equal-Weight Ra - GuruFocus
Barclays initiates Biogen stock coverage with $185 price target - Investing.com
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Boosts Stock Position in Biogen Inc. $BIIB - MarketBeat
New Biogen Chair Freire May Recast Partnerships And Capital Priorities - Yahoo Finance
Eisai & Biogen Canada Disagree With Canada's Drug Agency's Leqembi Reimbursement Rejection - TradingView
Eisai Maintains Commitment to People Living with Early Alzheimer's Disease Despite CDA-AMC Draft Recommendation: Patients Deserve Access to Effective Treatment - Newswire Canada
Assessing Biogen (BIIB) Valuation As Shares Gain 18.1% In 30 Days And 42% Over One Year - Yahoo Finance
Biogen (BIIB) Valuation Check After Earnings Momentum And Analyst Optimism - simplywall.st
NEOS Investment Management LLC Boosts Position in Biogen Inc. $BIIB - MarketBeat
Multiple Sclerosis Therapeutics Market to Reach USD 46.22 - openPR.com
Aberdeen Group plc Cuts Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Global Amyotrophic Lateral Sclerosis Therapeutics Market Size/Share Worth USD 1964 Million by 2035 at 11.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Alzheimer's Therapeutics Market Research Report 2026-2036: Growing Global Burden of Alzheimer's Continues to Drive Demand - GlobeNewswire Inc.
Biogen head of pharm ops Murphy buys $585 in stock By Investing.com - Investing.com Canada
Biogen head of pharm ops Murphy buys $585 in stock - Investing.com
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Wedbush lifts PT on Biogen Inc. (BIIB) to $187 from $178 – here’s why - MSN
5,611 Shares in Biogen Inc. $BIIB Purchased by Caprock Group LLC - MarketBeat
What Price Targets Have Wall Street Analysts Set for Biogen Shares? - Bitget
What Are Wall Street Analysts' Target Price for Biogen Stock? - Barchart.com
AlphaQuest LLC Sells 10,789 Shares of Biogen Inc. $BIIB - MarketBeat
Biogen Appoints Dr. Gabriela Freire as Board Chair While Immunic Inc. Searches for New CEO - geneonline.com
Early Diagnosis Kit for Alzheimer's Disease Market Outlook - openPR.com
Rhumbline Advisers Has $40.51 Million Position in Biogen Inc. $BIIB - MarketBeat
What are Biogen Inc.’s recent SEC filings showingMarket Risk Report & Growth Oriented Trade Recommendations - mfd.ru
Biogen’s New Therapies Surpass US$1 Billion In Sales Might Change The Case For Investing In BIIB - simplywall.st
LSV Asset Management Grows Position in Biogen Inc. $BIIB - MarketBeat
Oppenheimer & Co. Inc. Has $1.91 Million Stock Position in Biogen Inc. $BIIB - MarketBeat
Clinically Isolated Syndrome Treatment Market Size 2030 US$ 2.4 - openPR.com
BIIB: Late-stage lupus therapies and a diverse immunology pipeline target major unmet needs - TradingView
Biogen Spotlights Lupus Pipeline at Piper Sandler Symposium: Litifilimab, Dapirolizumab in Focus - MarketBeat
Wedbush Lifts PT on Biogen Inc. (BIIB) to $187 From $178 – Here’s Why - Insider Monkey
Wedbush Lifts PT on Biogen Inc. (BIIB) to $187 From $178Here's Why - Finviz
Is Biogen (NASDAQ:BIIB) Using Too Much Debt? - 富途牛牛
There May Be Reason For Hope In Biogen's (NASDAQ:BIIB) Disappointing Earnings - simplywall.st
Krilogy Financial LLC Invests $1.18 Million in Biogen Inc. $BIIB - MarketBeat
Biogen's (NASDAQ:BIIB) Soft Earnings Don't Show The Whole Picture - Yahoo Finance
The 5 Most Interesting Analyst Questions From Biogen's Q4 Earnings Call - Finviz
Biogen Inc. $BIIB Shares Sold by Illinois Municipal Retirement Fund - MarketBeat
The 5 Most Interesting Analyst Questions From Biogen’s Q4 Earnings Call - Yahoo Finance
Maria Freire to replace Caroline Dorsa as Biogen chair - The Pharma Letter
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.78%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):